Key result
The capsid binders GPP3, NLD, and ALD demonstrated potent in vitro antiviral activity against a wide range of enteroviruses, with NLD showing an EC50 of 0.00012 μM against Coxsackievirus A16.
Population
Coxsackievirus A16 and a panel of enteroviruses evaluated via crystallography, in silico docking, and…
Design
Preclinical
Authors
Loading...
Premature for clinical use; leaves open broad-spectrum enterovirus therapeutic development.
Effect estimate: EC50 0.00012 μM for NLD against CVA16
Structural elucidation of CVA16 with GPP3 and subsequent meta-analysis of capsid binders provide a basis for designing broad-spectrum anti-enterovirus therapeutics.
Colibus et al. (2015) studied Enterovirus infection (Hand, foot and mouth disease). Capsid binders (GPP3, NLD, ALD) vs. Untreated controls was evaluated on Antiviral activity (EC50) (EC50 0.00012 μM for NLD against CVA16). The capsid binders GPP3, NLD, and ALD demonstrated potent in vitro antiviral activity against a wide range of enteroviruses, with NLD showing an EC50 of 0.00012 μM against Coxsackievirus A16.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: